The Latest Breaking News from ABBV

These two are the calm outperformers that might have been overlooked.

United Parcel Service, PepsiCo, and AbbVie are healthy dividend payers whose analyst trends support an outlook for price strength in 2026.

Win through diversification: mix stable, income-generating Dividend Aristocrats for growth, reliability, and long-term returns.

Traders are increasingly turning to zero-days-to-expiration (0DTE) options to target fast-moving market reactions, including earnings announcements. The high leverage and compressed timeframe offered by these setups can deliver outsized returns, but those same dynamics leave little margin for error when it comes to timing and execution.

Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

AbbVie beats earnings and raises guidance as Skyrizi and Rinvoq fuel growth, setting the stage for ABBV stock to hold $250 as a new floor

AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.

Here are three big pharma stocks that can reward patient investors with a proven history of stability, dividends, and long-term growth potential

On CNBC's “Halftime Report Final Trades” on Tuesday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he is staying long on AbbVie Inc. (NYSE:ABBV).